Business Context and Reporting Period
Company: BIO-RAD LABORATORIES, INC.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended June 30, 2005
Business Overview: Bio-Rad is a multinational manufacturer and distributor of Life Science research and Clinical Diagnostics products. The company operates two primary segments: Life Science and Clinical Diagnostics. Approximately 63% of sales are international, creating exposure to currency fluctuations.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended June 30, 2005 |
3 Months Ended June 30, 2004 |
6 Months Ended June 30, 2005 |
6 Months Ended June 30, 2004 |
|---|---|---|---|---|
| Net Sales | $291,302 | $260,546 | $590,473 | $523,295 |
| Gross Profit | $160,643 | $149,661 | $327,049 | $298,925 |
| Gross Margin % | 55.1% | 57.4% | 55.4% | 57.1% |
| Net Income | $18,388 | $22,863 | $51,882 | $44,841 |
| Diluted EPS (Net Income) | $0.69 | $0.86 | $1.95 | $1.69 |
| Operating Cash Flow (6mo) | $27,818 (2005) vs $47,544 (2004) | |||
| Cash & Equivalents (End of Period) | $252,132 | |||
| Total Debt (Current + Long-term) | $437,343 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11.8% in Q2 2005 and 12.8% for the six-month period compared to 2004. Currency fluctuations (weaker US dollar) contributed approximately $8.7 million to Q2 sales and $18.5 million to the six-month sales. On a currency-neutral basis, sales grew 8.5% in Q2 and 9.3% for the six months.
- Profitability: While revenue grew, Net Income for Q2 2005 decreased to $18.4 million from $22.9 million in Q2 2004. This decline is largely due to the absence of a $3.4 million gain on divestiture recorded in Q2 2004 from discontinued operations. Income from continuing operations increased slightly to $18.4 million from $20.3 million.
- Margins: Consolidated gross margins declined to 55.1% in Q2 2005 from 57.4% in Q2 2004. The Life Science segment margin declined approximately 6% due to lower average selling prices for BSE tests, increased amortization of intangibles from the MJ Research acquisition, and inventory provisions.
- Expenses: Interest expense increased significantly ($3.1 million in Q2) due to higher average indebtedness ($435.9 million in Q2 2005 vs. $234.8 million in Q2 2004) following the issuance of $200 million in Senior Subordinated Notes in December 2004.
- Discontinued Operations: In Q1 2005, the company recognized a $4.0 million gain related to the settlement of lease commitments for the discontinued confocal microscopy product line. No sales or operating losses occurred in this segment for the six months ended June 30, 2005.
Guidance, Outlook, Risks, and Unusual Items
- Legal Proceedings (MJ Research): A significant litigation risk exists regarding patent infringement claims by Applera and Roche against MJ Research (acquired by Bio-Rad in 2004). A jury awarded damages of $35.4 million (enhanced from $19.8 million) plus attorney fees. Bio-Rad has established a $50.0 million litigation accrual and posted a $37.2 million surety bond (collateralized by $35.6 million restricted cash) to stay enforcement pending appeal. The company is opposing a motion to join Bio-Rad as a defendant.
- Acquisition Activity: Bio-Rad submitted a proposal to acquire BioSource International, Inc. for $8.50 per share, which was rejected. Subsequently, Invitrogen agreed to acquire BioSource for $12.50 per share. Bio-Rad currently owns approximately 6.9% of BioSource.
- Market Conditions: The BSE (Bovine Spongiform Encephalopathy) testing market faces competitive pricing pressures and lower average selling prices. The Life Science market is growing at approximately 5% (currency neutral), while the Clinical Diagnostics market is growing at approximately 3%.
- Stock-Based Compensation: The company currently follows APB Opinion No. 25 and records no stock-based compensation expense. However, it must adopt SFAS 123(R) effective January 1, 2006, which will require fair value recognition of stock options, potentially impacting future earnings.
- Liquidity: Management believes cash, cash equivalents ($252.1 million), short-term investments ($91.3 million), and available credit ($145.0 million under a $150.0 million facility) are adequate to meet current objectives.
Investor Verification Checklist
- Legal Exposure: Verify the status of the MJ Research patent litigation appeal and the potential for additional liability beyond the $50 million accrual, including attorney fees and potential injunctions.
- Margin Trends: Monitor the Life Science segment gross margins, specifically the impact of BSE test pricing and the integration of MJ Research intangibles.
- Debt Service: Assess the impact of increased interest expense on future cash flows given the $437 million total debt load.
- Accounting Changes: Evaluate the projected impact of adopting SFAS 123(R) on net income and EPS starting in fiscal year 2006.
- Currency Sensitivity: Review the company's hedging strategies given that 63% of sales are international and results are sensitive to US dollar strength.